Combining Esketamine With Other Antidepressants Leads To Better Clinical Outcomes For People with Treatment Resistant Depression

A recent study tracking outcomes for people with treatment-resistant depression (TRD) who were treated with esketamine and serotonin-norepinephrine reuptake inhibitors (SNRIs) compared to people with TRD who were treated with esketamine combined with serotonin reuptake inhibitors (SSRIs) found differences between the groups. The findings highlight that the choice of antidepressant combined with esketamine can significantly impact clinical outcomes in TRD, the researchers concluded.

Findings include:

Those in the esketamine and SNRI group had significantly lower all-cause mortality (5.3% vs 9.1%), hospitalization rates (0.1% vs 0.2%), and depression relapses (14.8% vs 21.2 . . .